Zannes Maria

SEC source: 0001493152-25-002150 · ownership.xml · nonDerivative · entry 1

Zannes Maria · CIK 0001481928 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 280,359

F1 · shares: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025.

SEC source: 0001493152-24-026087 · ownership.xml · nonDerivative · entry 1

Zannes Maria · CIK 0001481928 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 243,322

F1 · shares: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024.

SEC source: 0001493152-24-023998 · ownership.xml · nonDerivative · entry 1

Zannes Maria · CIK 0001481928 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,538

F1 · shares: Grant of restricted shares of common stock, par value $0.007 per share, that vest immediately.

SEC source: 0001493152-24-015791 · ownership.xml · derivative · entry 3

Zannes Maria · CIK 0001481928 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 64,848 shares

Expires 2024-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vested in 7 equal monthly installments beginning on April 28, 2014.

SEC source: 0001493152-24-015791 · ownership.xml · nonDerivative · entry 2

Zannes Maria · CIK 0001481928 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,242

F1 · kind: Represents shares withheld to cover the exercise price of the options exercised.

SEC source: 0001493152-24-015791 · ownership.xml · nonDerivative · entry 1

Zannes Maria · CIK 0001481928 · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 229,506

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001493152-24-004766 · ownership.xml · nonDerivative · entry 1

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,658

F1 · shares: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024.

SEC source: 0001493152-24-003696 · ownership.xml · nonDerivative · entry 2

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,773

F2 · shares: Represents a grant from the Issuer to Ms. Zannes of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

SEC source: 0001493152-24-003696 · ownership.xml · nonDerivative · entry 1

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,105

F1 · shares: Represents a grant from Issuer to Ms. Zannes of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

SEC source: 0001493152-23-023817 · ownership.xml · nonDerivative · entry 4

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,238

F4 · shares: Represents a grant from the Issuer to Ms. Zannes of 10,245 restricted shares of Common Stock, on July 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

SEC source: 0001493152-23-023817 · ownership.xml · nonDerivative · entry 3

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,993

F3 · shares: Represents a grant of 26,178 shares of Common Stock to Ms. Zannes on June 6, 2023 pursuant to Unanimous Written Consent of the Board of Directors of the Issuer dated November 17, 2022.

SEC source: 0001493152-23-023817 · ownership.xml · nonDerivative · entry 2

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,815

F2 · shares: Represents a grant from the Issuer to Ms. Zannes of 9,920 restricted shares of Common Stock on April 15, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest one-third on the date of grant, one-third on May 1, 2023 and the remaining shares on June 1, 2023, provided Ms. Zannes continues to serve as a director, and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

SEC source: 0001493152-23-023817 · ownership.xml · nonDerivative · entry 1

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,895

F1 · shares: Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Ms. Zannes of 8,227 restricted shares of common stock, par value $0.007 (the "Common Stock"), on January 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

SEC source: 0001493152-22-033283 · ownership.xml · nonDerivative · entry 3

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,668

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F5 · kind: Represents a grant from the Issuer to Ms. Zannes of 18,099 restricted shares of Common Stock on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 1,508 shares of Common Stock and the last of which will be of the remaining 1,511 shares of Common Stock, subject to Ms. Zannes's continuous service to the Issuer through each vesting date.

F5 · shares: Represents a grant from the Issuer to Ms. Zannes of 18,099 restricted shares of Common Stock on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 1,508 shares of Common Stock and the last of which will be of the remaining 1,511 shares of Common Stock, subject to Ms. Zannes's continuous service to the Issuer through each vesting date.

SEC source: 0001493152-22-033283 · ownership.xml · derivative · entry 7

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,571

Underlying: Common Stock · 23,571 shares

Expires 2027-08-11

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F4 · derivative.exercise_price: Represents a right to purchase 23,571 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Ms. Zannes on August 11, 2022 as consideration for funds Ms. Zannes paid to the Issuer for her unsecured convertible promissory note, dated August 11, 2022.

F4 · price: Represents a right to purchase 23,571 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Ms. Zannes on August 11, 2022 as consideration for funds Ms. Zannes paid to the Issuer for her unsecured convertible promissory note, dated August 11, 2022.

F4 · derivative.exercise_date: Represents a right to purchase 23,571 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Ms. Zannes on August 11, 2022 as consideration for funds Ms. Zannes paid to the Issuer for her unsecured convertible promissory note, dated August 11, 2022.

SEC source: 0001493152-22-033283 · ownership.xml · derivative · entry 6

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,672 shares

Expires 2022-10-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F3 · derivative.exercise_price: In connection with the IPO closing on September 6, 2022, the $99,423.12 of outstanding principal and accrued but unpaid interest of Ms. Zannes's unsecured convertible promissory note, dated August 11, 2022, automatically converted into 23,672 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

F3 · derivative.exercise_date: In connection with the IPO closing on September 6, 2022, the $99,423.12 of outstanding principal and accrued but unpaid interest of Ms. Zannes's unsecured convertible promissory note, dated August 11, 2022, automatically converted into 23,672 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

SEC source: 0001493152-22-033283 · ownership.xml · nonDerivative · entry 2

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,569

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F3 · shares: In connection with the IPO closing on September 6, 2022, the $99,423.12 of outstanding principal and accrued but unpaid interest of Ms. Zannes's unsecured convertible promissory note, dated August 11, 2022, automatically converted into 23,672 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

F3 · price: In connection with the IPO closing on September 6, 2022, the $99,423.12 of outstanding principal and accrued but unpaid interest of Ms. Zannes's unsecured convertible promissory note, dated August 11, 2022, automatically converted into 23,672 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

SEC source: 0001493152-22-033283 · ownership.xml · derivative · entry 5

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,326

Underlying: Common Stock · 16,326 shares

Expires 2027-08-31

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F2 · derivative.exercise_price: The reported securities are included within 16,326 Units purchased by Ms. Zannes for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

F2 · price: The reported securities are included within 16,326 Units purchased by Ms. Zannes for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

SEC source: 0001493152-22-033283 · ownership.xml · derivative · entry 4

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,326

Underlying: Common Stock · 16,326 shares

Expires 2027-08-31

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F2 · derivative.exercise_price: The reported securities are included within 16,326 Units purchased by Ms. Zannes for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

F2 · price: The reported securities are included within 16,326 Units purchased by Ms. Zannes for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

SEC source: 0001493152-22-033283 · ownership.xml · nonDerivative · entry 1

Zannes Maria · CIK 0001481928 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,897

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F2 · price: The reported securities are included within 16,326 Units purchased by Ms. Zannes for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.